Avidity Biosciences Stock News

The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse. The post Highly Rated Avidity Biosciences Hammered After Side Effect Sideline

Shares of Avidity Biosciences Inc. RNA, +1.13% tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price t

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Avidity Biosciences press release (NASDAQ:RNA): Q4 GAAP EPS of -$0.82.Revenue of $1.85M (-13.6% Y/Y).

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended…

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

LA JOLLA, Calif., Feb. 11, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleo

Avidity Biosciences, Inc. (NASDAQ:RNA)s share price gapped down before the market opened on Friday . The stock had previously closed at $24.32, but opened at $22.15. Avidity Biosciences shares last traded at $22.71, with a volume of 101 shares changing hands. RNA has been the topic of a number of research analyst reports. Evercore ISI []

Avidity Biosciences (NASDAQ:RNA) had its price objective lifted by SVB Leerink from $36.00 to $53.00 in a report issued on Friday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Evercore ISI began coverage on Avidity Biosciences […]

Wells Fargo & Company restated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA) in a research note issued to investors on Friday morning, TipRanks reports. They currently have a $59.00 price objective on the biotechnology companys stock. A number of other equities analysts also recently commented on the stock. SVB Leerink boosted their target []